Who
Kent Kresa
Director
Company insider
Files Form 4 as: Director, NuScale Power; Director, MannKind; Director, Fluor; Director, Avery Dennison; Director, General Motors.
In numbers
- Trades disclosed
- 270
- Buys
- 2
- Sells
- 0
- Bought
- $1.4M
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 30 Dec 2005
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | SMR NuScale PowerNuclear Technology | SEC FORM 4 Code A | —3,338 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | SMR NuScale PowerNuclear Technology | SEC FORM 4 Code A | —2,702 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | SMR NuScale PowerNuclear Technology | SEC FORM 4 Code A | —2,702 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | SMR NuScale PowerNuclear Technology | SEC FORM 4 Code A | —8,681 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | SMR NuScale PowerNuclear Technology | SEC FORM 4 Code A | —8,681 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SMR NuScale Poweroption or derivative · Nuclear Technology | SEC FORM 4 Code A | —3,946 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SMR NuScale Poweroption or derivative · Nuclear Technology | SEC FORM 4 Code A | —3,946 at $0.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | SMR NuScale PowerNuclear Technology | SEC FORM 4 Code A | $52K3,702 at $14.17 | filing |
| 31 Dec 2025filed 5 Jan 2026 | SMR NuScale PowerNuclear Technology | SEC FORM 4 Code A | $52K3,702 at $14.17 | filing |
| 30 Sep 2025filed 2 Oct 2025 | SMR NuScale PowerNuclear Technology | SEC FORM 4 Code A | $45K1,262 at $36.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | SMR NuScale PowerNuclear Technology | SEC FORM 4 Code A | $27K695 at $39.56 | filing |
| 28 May 2025filed 30 May 2025 | SMR NuScale PowerNuclear Technology | SEC FORM 4 Code A | —3,109 at $0.00 | filing |
| 13 May 2025filed 15 May 2025 | SMR NuScale Poweroption or derivative · Nuclear Technology | SEC FORM 4 Code C | —19,783 at $0.00 | filing |
| 13 May 2025filed 15 May 2025 | SMR NuScale PowerNuclear Technology | SEC FORM 4 Code C | —19,783 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | SMR NuScale PowerNuclear Technology | SEC FORM 4 Code A | $27K1,942 at $14.16 | filing |
| 31 Dec 2024filed 10 Jan 2025 | SMR NuScale PowerNuclear Technology | SEC FORM 4 Code A | $27K1,533 at $17.93 | filing |
| 30 Sep 2024filed 2 Oct 2024 | SMR NuScale PowerNuclear Technology | SEC FORM 4 Code A | —2,374 at $0.00 | filing |
| 30 Jun 2024filed 2 Jul 2024 | SMR NuScale PowerNuclear Technology | SEC FORM 4 Code A | —2,352 at $0.00 | filing |
| 28 May 2024filed 29 May 2024 | SMR NuScale PowerNuclear Technology | SEC FORM 4 Code A | —11,603 at $0.00 | filing |
| 15 May 2024filed 17 May 2024 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —35,047 at $0.00 | filing |
News
Comparing MannKind (NASDAQ:MNKD) & Iovance Biotherapeutics (NASDAQ:IOVA)MNKD · tickerreport.com · 15 Oct 2026MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)MNKD · manilatimes.net · 10 Oct 2026
0 headlines in the last 90 days name Kent Kresa; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.